PDF(Sci-hub)
Abstract：
The coronavirus disease (COVID-19), which is also known as acute respiratory syndrome coronavirus-2 (SARS-CoV2) is a transmissible disease, has phenotypes varying from asymptomatic to Acute Respiratory Distress Syndrome (ARDS) or multiple organ dysfunction syndrome (MODS) and ultimately death in certain cases. Coagulation disorders are being frequently reported amongst these patients and the pathogenesis is still not completely understood. Proposed mechanisms for these coagulopathies comprise a hypercoagulable state with micro- and/or macro-thrombosis in the vessels. A number of changes have been reported or proposed in circulating prothrombotic factors in COVID-19 patients and includes elevation in both factor VIII and fibrinogen, circulating prothrombotic microparticles and hyperviscosity. The COVID-19 patients are showing varied coagulopathies and are at high risk for venous thromboembolism (VTE) which demands an early intervention. This paper reviews the evolving data regarding the evaluation and managing of coagulopathies in patients with COVID-19.
摘要：
冠状病毒病（COVID-19），也被称为急性呼吸道综合症冠状病毒-2（SARS-CoV2）是一种传染性疾病，具有从无症状到急性呼吸窘迫综合征（ARDS）或多器官功能障碍综合征（MODS）的表型，在某些情况下最终死亡。在这些患者中经常报道凝血障碍，其发病机理仍未完全了解。这些凝血病的建议机制包括血管中的微血栓和/或大血栓形成的高凝状态。已经报道或提出了COVID-19患者循环血栓前因子的许多变化，包括因子VIII和纤维蛋白原的升高，循环血栓前微粒和高粘度。COVID-19患者表现出不同的凝血功能障碍，静脉血栓栓塞(VTE)的风险很高，需要早期干预。本文回顾了有关COVID-19患者凝血功能障碍评估和管理的不断发展的数据。
